Arnaud A, Charpin J
Eur J Respir Dis Suppl. 1982;122:126-31.
Fourteen patients with acute asthma were randomly distributed between two equally large groups. They received a two-hour intravenous infusion twice a day. Group 1 was treated with corticosteroids and group 2 with corticosteroids and the beta 2-adrenergic agonist terbutaline. The effects of treatment were evaluated by clinical examination and measurement of FEV1 on four consecutive days; in the morning before treatment and then hourly for six hours. The mean FEV1 remained statistically unchanged in group 1. In group 2, mean FEV1 showed a slight but significant improvement on the first day, then a more and more marked increase on the second, third and fourth days. Comparison between the two groups showed that differences in mean FEV1 were significant at the first, second and third hour of the first day and from the first to the sixth hour on the other three days. An additional group of seven patients was treated with beta 2-adrenergic agonist alone. In this group, only a slight increase in FEV1 was noted. This work might suggest an advantage in combining bronchodilators and corticosteroids in the treatment of severe acute asthma.
14名急性哮喘患者被随机分为两个同样规模的大组。他们每天接受两次两小时的静脉输注。第1组接受皮质类固醇治疗,第2组接受皮质类固醇和β2 - 肾上腺素能激动剂特布他林治疗。通过临床检查和连续四天测量第一秒用力呼气量(FEV1)来评估治疗效果;在治疗前的早晨以及随后的六个小时内每小时测量一次。第1组的平均FEV1在统计学上保持不变。在第2组中,平均FEV1在第一天有轻微但显著的改善,然后在第二天、第三天和第四天有越来越明显的增加。两组之间的比较表明,第一天的第一、第二和第三小时以及另外三天的第一至第六小时,平均FEV1的差异具有统计学意义。另一组7名患者仅接受β2 - 肾上腺素能激动剂治疗。在该组中,仅观察到FEV1有轻微增加。这项研究可能表明在重度急性哮喘的治疗中联合使用支气管扩张剂和皮质类固醇具有优势。